Whole-Body Cryotherapy Decreases the Levels of Inflammatory, Oxidative Stress, and Atherosclerosis Plaque Markers in Male Patients with Active-Phase Ankylosing Spondylitis in the Absence of Classical Cardiovascular Risk Factors
Table 4
Activities of antioxidant enzymes (mean value ± standard deviation (SD)) in AS patients before and after the completion of a cycle of ten whole-body cryotherapy procedures with subsequent kinesiotherapy (WBC group) or a cycle of ten kinesiotherapy procedures only (KT group), with statistical analyses. (p): plasma; (e): erythrocyte lysates; Δ: difference prior to post treatment.
Parameters
WBC group
KT group
Total SOD (p) (NU/ml)
Before
13.4 ± 2.13
12.3 ± 1.85
0.145
After
12.1 ± 1.88
1.7 ± 2.49
0.632
0.233
0.301
Δ
−1.28 ± 3.13
−0.60 ± 2.65
0.512
SOD-Mn (p) (NU/ml)
Before
5.37 ± 2.75
4.56 ± 1.86
0.336
After
6.27 ± 0.99
5.02 ± 1.64
0.015
0.163
0.642
Δ
0.90 ± 2.80
0.46 ± 2.46
0.642
SOD-CuZn (p) (NU/ml)
Before
8.09 ± 2.74
7.80 ± 2.21
0.749
After
7.15 ± 1.32
7.05 ± 3.09
0.902
0.326
0.063
Δ
−0.93 ± 2.77
−0.75 ± 2.72
0.854
Total SOD (e) (NU/mgHb)
Before
85.5 ± 17.3
128.0 ± 11.2
<0.001
After
90.5 ± 11.9
111.0 ± 15.6
<0.001
0.438
0.001
Δ
5.02 ± 17.3
−17.1 ± 11.8
<0.001
CAT (e) (IU/mgHb)
Before
385.0 ± 70.3
425.0 ± 53.6
0.084
After
375.0 ± 58.3
412.0 ± 58.6
0.088
0.535
0.352
Δ
−9.9 ± 57.0
−13.0 ± 54.0
0.876
GPx (e) (IU/gHb)
Before
31.2 ± 4.90
29.9 ± 2.84
0.363
After
29.1 ± 2.97
20.4 ± 5.05
<0.001
0.039
0.001
Δ
−2.09 ± 3.61
−9.49 ± 6.74
0.001
GR (e) (IU/gHb)
Before
1.72 ± 0.56
2.07 ± 0.52
0.043
After
1.54 ± 0.60
1.65 ± 0.59
0.078
0.469
0.002
Δ
−0.18 ± 0.80
−0.42 ± 0.41
0.622
: statistical significance of differences between both groups of patients; : statistical significance of differences between values before and after treatment in particular groups of subjects.
